FDA guidance
Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings…
FDA guidance · Final · issued Jul 27, 2022
Key facts
| Title | Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Jul 27, 2022 |
| Center | Office of the Commissioner |
| Issuing office | Oncology Center of Excellence, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics, Drugs |
| Topics | Clinical Trials |
| Docket number | FDA-2020-D-1802 |
| Comments close | Aug 24, 2021 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents